DACLIZUMAB is a specific IL2 receptor-targeting drug, which is related to GZMB, IL2RB, and IL2RG, and research indicates its therapeutic potential in the experimental arthritis model induced by CIA (Brok et al., 2001). The gene discussed is IL2RG; the disease is Arthritis.